Treatment and management of Crimean-Congo hemorrhagic fever
Journal of Vector Borne Diseases · 2026
DOI: 10.4103/jvbd.jvbd_18_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Vector Borne Diseases, 2026. Verfasst von Rukiyye Bulut und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Clinical Microbiology, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye. Hauptthemen laut MEDLINE: Hemorrhagic Fever, Crimean, Ribavirin, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background & objectives: Crimean-Congo hemorrhagic fever (CCHF) is a tick-bome viral infection with a wide geographic distribution globally. The clinical severity of CCHF varies, with reported mortality rates reaching up to 60%. Despite its spread to new geographic areas and its potential to cause severe and fatal disease, no approved vaccine or antiviral treatment is currently available. Studies on the use of ribavirin for CCHF have yielded conflicting results. Consequently, many physicians manage CCHF patients with supportive care. In this study, we share the positive outcomes observed in CCHF patients who were managed exclusively with supportive treatment without the use of ribavirin.
Methods
The epidemiological characteristics, laboratory results and treatment outcomes of patients with CCHF diagnosis followed up in our clinic between April 1 2020, and September 31 2023 were evaluated retrospectively.
Results
The study included 20 patients (5 females and 15 male) with confirmed CCHF. Based on the Severity Scoring Index (SSI) scores, 7 patients with SSI 0-2 were classified as mild cases, 12 patients with SSI 3-9 as moderate cases, and 1 patient with SSI 10-13 as a severe case. No patients received ribavirin as part of their treatment. All patients were managed with supportive care, and no mortality was observed. Interpretation & conclusion: Supportive care remains the standard treatment for CCHF management. The effectiveness of ribavirin in CCHF remains unclear.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases and Clinical Microbiology, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye.
Zitieren
APA
Bulut, R., Kandemir, B., Erayman, İ., Keskin, P. B., & Kurt, E. K. (2026). Treatment and management of Crimean-Congo hemorrhagic fever. Journal of Vector Borne Diseases. https://doi.org/10.4103/jvbd.jvbd_18_25
Vancouver
Bulut R, Kandemir B, Erayman İ, Keskin PB, Kurt EK. Treatment and management of Crimean-Congo hemorrhagic fever. Journal of Vector Borne Diseases. 2026. doi:10.4103/jvbd.jvbd_18_25
BibTeX
@article{Bulut2026,
author = {Bulut, Rukiyye and Kandemir, Bahar and Erayman, İbrahim and Keskin, Pınar Belviranlı and Kurt, Esma Kepenek},
title = {Treatment and management of Crimean-Congo hemorrhagic fever},
journal = {Journal of Vector Borne Diseases},
year = {2026},
doi = {10.4103/jvbd.jvbd_18_25}
}
EUVIMED